Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

被引：0

作者：

Ignacio Bernabéu

Carmen Fajardo

Mónica Marazuela

Fernando Cordido

Eva María Venegas

Pedro de Pablos-Velasco

Gonzalo Piedrola Maroto

María Pilar Olvera

Isabel Pavón de Paz

Davide Carvalho

Carme Romero

Guillermo De la Cruz

Cristina Álvarez Escolá

机构：

[1] Hospital Clínico Universitario Santiago de Compostela,Endocrinology and Nutrition Department

[2] Hospital Universitario de La Ribera,Endocrinology and Nutrition Department

[3] Hospital Universitario La Princesa,Endocrinology and Nutrition Department

[4] Universidad Autónoma Madrid,Faculty of Health Sciences and INIBIC, University of A Coruña, and Endocrinology and Nutrition Department

[5] Instituto Princesa,Endocrinology and Nutrition Department

[6] Complejo Hospitalario Universitario de A Coruña,Endocrinology and Nutrition Department

[7] Hospital Universitario Virgen del Rocío,Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário São João

[8] University of Las Palmas de Gran Canaria. Spain,Endocrinology and Nutrition Department

[9] Endocrinology and Nutrition Departament Hospital Universitario Virgen de las Nieves,undefined

[10] Endocrinology and Nutrition Departament,undefined

[11] Hospital Universitario Nuestra Señora de Candelaria,undefined

[12] Endocrinology and Nutrition Departament,undefined

[13] Hospital Universitario de Getafe,undefined

[14] Faculty of Medicine,undefined

[15] i3S,undefined

[16] Universidade do Porto,undefined

[17] Adknoma Health Research S.L.,undefined

[18] Ipsen Pharma,undefined

[19] Hospital Universitario La Paz,undefined

来源：

Endocrine | 2020年 / 70卷

关键词：

Acromegaly; Lanreotide; Insulin-like growth factor 1; Somatostatin; Growth hormone;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：575 / 583

页数：8

共 50 条

[31] Effectiveness of slow-release lanreotide, a long-acting somatostatin analogue, in the treatment of acromegaly
Chang, TC
Chang, TJ
Chen, MH
Hsiao, YL
Tsai, KS
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 1998, 97 (10) : 684 - 689
[32] ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly
Alvarez-Escola, Cristina
Maria Venegas-Moreno, Eva
Antonio Garcia-Arnes, Juan
Blanco-Carrera, Concepcion
Marazuela-Azpiroz, Monica
Angeles Galvez-Moreno, Maria
Menendez-Torre, Edelmiro
Aller-Pardo, Javier
Salinas-Vert, Isabel
Resmini, Eugenia
Torres-Vela, Elena Maria
Gonzalo-Redondo, Maria Angeles
Vilchez-Joya, Ricardo
de Miguel-Novoa, Maria Paz
Halperin-Rabinovich, Irene
Paramo-Fernandez, Concepcion
de la Cruz-Sugranyes, Guillermo
Houchard, Aude
Miguel Pico-Alfonso, Antonio
ENDOCRINOLOGIA DIABETES Y NUTRICION, 2019, 66 (05): : 320 - 329
[33] Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly
Colao, A
Marzullo, P
Ferone, D
Marinò, V
Pivonello, R
Di Somma, C
Di Sarno, A
Giaccio, A
Lombardi, G
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1999, 22 (01) : 40 - 47
[34] Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly
Salvatori, Roberto
Nachtigall, Lisa B.
Cook, David M.
Bonert, Vivien
Molitch, Mark E.
Blethen, Sandra
Chang, Stephen
PITUITARY, 2010, 13 (02) : 115 - 122
[35] Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland
Stoermann, Sylvere
Schopohl, Jochen
Bullmann, Catharina
Terkamp, Christoph
Christ-Crain, Mirjam
Finke, Reinhard
Flitsch, Joerg
Kreitschmann-Andermahr, Ilonka
Luger, Anton
Stalla, Gunter
Houchard, Aude
Helbig, Dorit
Petersenn, Stephan
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2021, 129 (03) : 224 - 233
[36] Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly
A. Colao
P. Marzullo
D. Ferone
V. Marinò
R. Pivonello
C. Di Somma
A. Di Sarno
A. Giaccio
G. Lombardi
Journal of Endocrinological Investigation, 1999, 22 : 40 - 47
[37] Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)
Zhenmei An
Ting Lei
Lian Duan
Pei Hu
Zhongping Gou
Lihui Zhang
Lucie Durand-Gasselin
Nan Wang
Yan Wang
Feng Gu
BMC Endocrine Disorders, 20
[38] Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly
Roberto Salvatori
Lisa B. Nachtigall
David M. Cook
Vivien Bonert
Mark E. Molitch
Sandra Blethen
Stephen Chang
Pituitary, 2010, 13 : 115 - 122
[39] High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study
Giustina, Andrea
Mazziotti, Gherardo
Cannavo, Salvatore
Castello, Roberto
Arnaldi, Giorgio
Bugari, Giovanna
Cozzi, Renato
Ferone, Diego
Formenti, Anna Maria
Gatti, Enza
Grottoli, Silvia
Maffei, Pietro
Maffezzoni, Filippo
Montini, Marcella
Terzolo, Massimo
Ghigo, Ezio
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (07) : 2454 - 2464
[40] Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery
Alvarez-Escola, Cristina
Cardenas-Salas, Jersy J.
Pelegrina, Beatriz
Sanz-Valtierra, Angel
Lecumberri, Beatriz
CLINICAL CASE REPORTS, 2015, 3 (11): : 945 - 948

← 1 2 3 4 5 →